Categories AlphaGraphs, Earnings, Technology
Infographic: Zoom Video Communications (ZM) Q1 2023 earnings results
Zoom Video Communications (NASDAQ: ZM) reported lower earnings and higher revenues for the first quarter of 2023. Earnings topped Wall Street’s expectations, while revenues matched the estimates.
Adjusted earnings, excluding special items, dropped to $1.03 per share in the first quarter from $1.32 per share a year earlier. Unadjusted net income was $113.6 million or $0.37 per share, compared to $227.4 million or $0.74 per share in the first quarter of 2022. The latest number beat the estimates.
At $1.07 billion, net revenues were up 12% year-over-year. The top line matched analysts’ forecasts. The company had around 98,900 enterprise customers at the end of the quarter, up 24% from the last fiscal year.
“In Q1, we launched Zoom Contact Center, Zoom Whiteboard, and Zoom IQ for Sales, demonstrating our continued focus on enhancing the customer experience and promoting hybrid work. We believe these innovative solutions will further expand our market opportunity for future growth and expansion with customers,” said Zoom’s CEO Eric Yuan.
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent
